- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02804035
Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product
Open Label First in Human Use Pilot Study of a To-Be-Marketed Drug-Device Combination Product (sc2Wear Furosemide Combination Product) in Subjects With Chronic Heart Failure
The proposed pilot study aims to gain experience with the first clinical use of the to-be marketed drug-device combination product, the sc2Wear Furosemide Combination Product and to assess methods and procedures for evaluation of product performance.
The objectives of this study are:
- To gain first in man experience of a novel drug-device combination product
- To evaluate the suitability of the methods and procedures for evaluating of the performance of the sc2Wear Pump
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be an open label, single-dose study to gain experience with first clinical use and to evaluate the suitability of the methods and procedures for evaluation of product performance of a to-be-marketed drug-device combination product (sc2WearTM Furosemide Combination Product) in a minimum of 20 adult male and female subjects previously diagnosed with mild to advanced heart failure (NYHA class II-IV). The study will enroll up to 30 Subjects to ensure a minimum of 20 evaluable Subjects. Methodology: Each Subject will complete Screening, Treatment, and Follow-Up Phases on an outpatient basis. During the Screening Phase, all Subjects who sign the informed consent form and satisfy the inclusion/exclusion criteria will be enrolled into the trial. Drug administration may start on the day of enrollment or be scheduled within 3 days of completion of Screening procedures. However, if the treatment visit doesn't occur within 3 days of initial screening, subjects may be rescreened and treated within 3 days of rescreening. The Treatment Phase comprises a preprogrammed bi-phasic 5 hour drug administration. Treatment Day observations will commence with pre-placement procedures and continue until one hour after device removal. Device preparation, placement and removal will be performed by study staff in accordance with product instructions for use. Removal will occur within
3 hours of completion of drug delivery (8 hours of start of administration). Subjects will return 5-7 days after the Treatment Day for a post treatment follow-up and photography. After preparation of the skin, the device will be placed on the upper abdominal area by clinical study staff. Subjects are advised to avoid strenuous physical activity or activities that could expose the device to moisture such as swimming, bathing or showering. Participants will be informed that marked diuresis may ensue after activation, and that they should avoid travel, operating a vehicle or other situations without immediate access to bathroom facilities. For each Subject, a reusable components (Activator) and a single-use unit (Cartridge) will be used. Following removal from the skin, the assembled device will be inspected and photographed by the site staff. The used device (assembled Cartridge and Activator) will be placed in a sealed container and returned for further inspection and measurement of residual volume in the device reservoir.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.
- Male and female Subjects ≥18 years of age
- New York Heart Association (NYHA) Class II-IV Heart Failure.
- In the opinion of the Investigator, able to participate in the study.
- If Subject is on oral diuretic, willing to suspend the oral furosemide or other loop diuretic treatment on the day of treatment (use of oral diuretic within 8 hours of start of treatment is not recommended)
- If Subject has significant body hair on the abdomen, willing to clip or shave the area where the device will be placed prior to treatment.
- Has the ability to understand the requirements of the study, and is willing to comply with all study procedures.
Exclusion Criteria:
- Contraindication to furosemide.
- History of chronic skin conditions requiring medical therapy.
- Skin reaction to medical adhesives or history of poor skin adherence of adhesives.
- Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
- Diabetic patients currently using an insulin pump and/or interstitial glucose monitors.
- Clinically significant abnormalities at Screening in safety laboratory tests.
- Hypokalemia - Potassium of < 3.6 mmol/L.
- Systolic BP (SBP) < 90 mm Hg.
- Temperature > 38°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment.
- History of major abdominal surgery affecting the site of device placement.
- Participation in another trial, within 30 days prior to Screening.
- History of hepatitis B, hepatitis C, or HIV
- History of current or recent alcohol abuse.
- Female subject who is pregnant or lactating.
- Any surgical or medical condition that in the opinion of the Investigator may interfere with participation in the study or that may affect the outcome of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sc2Wear Furosemide Combination Product
Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
|
Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence of Major Product Failure
Time Frame: 1-5 hours
|
Freedom from failures leading to infusion errors.
|
1-5 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Pain Tolerance
Time Frame: 1-5 hours
|
Subject-reported pain using 11 point numeric rating scale of 0 to 10.
|
1-5 hours
|
Local Skin Tolerance
Time Frame: 1-8 days
|
Adhesive site skin inspection for erythema, edema and other local reactions using 8 point scale.
|
1-8 days
|
Incidence of treatment-emergent Adverse Events and Serious Adverse Events
Time Frame: 1-8 days
|
1-8 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
-
US Department of Veterans AffairsCompleted
Clinical Trials on sc2Wear Furosemide
-
scPharmaceuticals, Inc.Completed
-
Steward St. Elizabeth's Medical Center of Boston...TerminatedHeart FailureUnited States
-
Adrian HernandezTerminatedDecompensated Heart Failure | Acute Heart FailureUnited States
-
NYU Langone HealthWithdrawnPremature Birth | Premature InfantUnited States
-
Johns Hopkins UniversityscPharmaceuticals, Inc.Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States, Canada
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBronchopulmonary DysplasiaUnited States
-
Jan Kochanowski UniversityRecruiting